Drug Profile
Research programme: AMPA antagonist - Schering AG
Latest Information Update: 07 Sep 2004
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Class
- Mechanism of Action AMPA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 15 Jun 2004 Discontinued - Preclinical for Stroke in Germany (unspecified route)
- 16 Dec 2003 No development reported - Preclinical for Stroke in Germany (unspecified route)
- 22 Jun 2000 Preclinical development for Stroke in Germany (Unknown route)